ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care-Slides - ORN Spring 2026

Slides - ORN Spring 2026 - Lynch, MD

Pdf Summary

This presentation reviews the emergence of <strong>medetomidine</strong> as a new illicit opioid adulterant and its major clinical implications. Medetomidine is an FDA-approved veterinary anesthetic and a highly selective <strong>alpha-2 agonist</strong>. In the illicit drug supply, it is most often found with fentanyl and can contribute to both <strong>prolonged overdose toxicity</strong> and a distinct, severe <strong>withdrawal syndrome</strong>.

Key toxicity features include persistent sedation after naloxone, miosis, sinus bradycardia, respiratory depression, and blood pressure instability that may shift from early hypertension to hypotension. Management is largely supportive: naloxone should still be given for possible opioid toxicity, but it will not reverse medetomidine effects. Most patients need oxygen and fluids; some require vasopressors or ventilation. Atipamezole is not recommended for human use.

The presentation emphasizes that <strong>medetomidine withdrawal is often rapid and severe</strong>, usually occurring within hours, with nausea/vomiting, marked tachycardia, severe hypertension, anxiety, diaphoresis, tremor, myoclonic jerks, delirium, and frequent ICU-level illness. Common associated findings include metabolic acidosis, elevated lactate, hypokalemia, QTc prolongation, troponin elevation, and occasionally PRES.

Recommended treatment is <strong>early and aggressive alpha-2 agonist therapy</strong>, often using clonidine or guanfacine, and for severe cases dexmedetomidine infusion with transition back to oral agents. Supportive care includes IV fluids, electrolyte correction, antiemetics, and treatment of concurrent opioid withdrawal with methadone or microdosed buprenorphine when appropriate.

Overall, the talk stresses that the changing drug supply requires rapid recognition, multidisciplinary coordination, extended observation, and low-barrier access to substance use treatment and harm reduction services.

Keywords

medetomidine

fentanyl

opioid adulterant

alpha-2 agonist

overdose toxicity

naloxone

withdrawal syndrome

clonidine

dexmedetomidine

harm reduction